Publications

https://scholar.google.com/citations?hl=en&user=UO2tpmAAAAAJ&view_op=list_works&sortby=pubdate

https://www.researchgate.net/profile/Hazem_Elewa

  1. Abdelkader NN, Awaisu A, Elewa H, Mahfoud Z, Al Abdulla SA, Owais A, El Hajj MS. Prescribing trends and patterns for antihypertensive agents in primary healthcare settings in Qatar: a retrospective observational study. Journal of Pharmaceutical Policy and Practice. 2025 Dec 31;18(1):2512183.
  2. Abdelkader N, Awaisu A, Elewa H, Al Abdulla SA, El Hajj MS. Primary care physicians’ perceptions of hypertension management in Qatar: A qualitative study using the theoretical domains framework. PLoS One. 2025 Apr 24;20(4):e0318527.
  3. Zaghloul N, Awaisu A, Mahfouz A, Ali Z, Alyafei S, Elewa H. Evaluating the appropriateness and the factors associated with sodium-glucose co-transporter 2 inhibitors prescribing in a Middle Eastern country: a cross-sectional study. International Journal of Clinical Pharmacy. 2025 Apr;47(2):314-24.
  4. Ibrahim A, Yusuff K, Awaisu A, Elewa H. Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review. Frontiers in Pharmacology. 2025 Feb 12;16:1523399.
  5. El-Bardissy A, Elshafei MN, Abdelgawad H, Mekkawi R, Eltahir A, Mohammed A, Am A, Elewa H. Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in nephrotic syndrome patients: a retrospective study. Thrombosis Journal. 2025 Jan 30;23(1):9.
  6. Fahmi AM, El Bardissy A, Saad MO, Fares A, Sadek A, Elshafei MN, Eltahir A, Mohamed A, Elewa H. Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population. Current Problems in Cardiology. 2024 Sep 22:102865.
  7. Fahmi AM, El Bardissy A, Saad MO, Elshafei MN, Bader L, Mahfouz A, Kasem M, Abdelsamad O, Elzouki A, Aquilante CL, Mraiche F, Elewa H. Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial). Clinical and Translational Science. 2024 Jun;17(6).
  8. Abdel-Latif R, Badji R, Mohammed S, Al-Muftah W, Mbarek H, Darwish D, Assaf D, Al-Badriyeh D, Elewa H, Afifi N, Masoodi NA. QPGx-CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies. Clinical and translational science. 2024 Jun;17(6):e13800.
  9. Alalawneh M, Awaisu A, Abdallah I, Elewa H, Danjuma M, Matar KM, ElKashlan AM, Elshayep Y, Ibrahim F, Rachid O. Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK). Clinical and Translational Science. 2024 Jun;17(6).
  10. Alalawneh M, Rachid O, Abdallah I, Mahfouz A, Elewa H, Danjuma MI, Mohamed AE, Awaisu A. Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data. European Journal of Clinical Pharmacology. 2023 Dec;79(12):1675-85.
  11. Abdelkader, N, Awaisu, A, Elewa, H, El Hajj, M. (2023). Prescribing patterns of antihypertensive medications: A systematic review of literature between 2010 and 2020. Exploratory Research in Clinical and Social Pharmacy. 11. 100315. 10.1016/j.rcsop.2023.100315.
  12. Elgendy HM, Ibrahim SM, Bader L, Mohammad RA, Ali ZO, Bejaoui MB, Hilani M, Ismail H, Elewa HF. Genetic Factors Associated with Morphine Consumption in Women Undergoing Laparoscopic Cholecystectomy: A Prospective Cohort Study. Journal of Pain Research. 2023 Dec 31:2407-17.
  13. Omar NE, Elewa H. Cisplatin-induced ototoxicity: a novel approach to an ancient problem. Pharmacogenetics and Genomics. 2023 Jul 1:10-97.
  14. Zaghloul N, Awaisu A, Mahfouz A, Alyafei S, Elewa H. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country. International Journal of Clinical Pharmacy. 2022 Sep 28:1-9.
  15. Osman A, Al-Badriyeh D, Hussain FN, Riaz S, Elewa H, Mraiche F. The design and implementation of an undergraduate health professional degree elective course on scientific writing, peer assessment, and critical appraisal. Currents in Pharmacy Teaching and Learning. 2022 Jun 1;14(6):765-72.
  16. Fahmi AM, Elewa H, El Jilany I. Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. International Journal of Clinical Pharmacy. 2022 Mar 5:1-9.
  17. Ali ZO, Bader L, Mohammed S, Arafa S, Arabi A, Cavallari L, Langaee T, Mraiche F, Rizk N, Awaisu A, Shahin MH, Elewa H. Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation. Pharmacogenetics and Genomics. 2022 Feb 21:10-97.
  18. El Rouby, N, Shahin M, Bader L, Khalifa S, Elewa H “Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations.” Clinical and translational science 15.2 (2022): 558-566.
  19. Aboelbaha S, Zolezzi M, Elewa H. Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review. Neuropsychiatr Dis Treat. 2021;17:2397-2419.
  20. Eljilany I, Elarref M, Shallik N, Elzouki AN, Bader L, El-Bardissy A, Abdelsamad O, Al-Badriyeh D, Cavallari LH, Elewa H. Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management. Pharmgenomics Pers Med. 2021;14:1069-1080.
  21. Eljilany I, Elewa H, Abdelsamad O, Abdelgelil M, Mahfouz A, Al Anany R, Al Yafei S, Al-Badriyeh D (2021) Bridging versus Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses. Current Problems in Cardiology:100839
  22. Eljilany I, Elarref M, Shallik N, Elzouki A-N, Mohammed A, Shoman B, Ibrahim S, Carr C, Al-Badriyeh D, Cavallari LH, Elewa H (2021) Periprocedural Anticoagulation Management of Patients receiving Warfarin in Qatar: A Prospective Cohort Study. Current Problems in Cardiology:100816
  23. AlMukdad S, Elewa H, Arafa S, Al-Badriyeh D. (2021). Short-and long-term cost-effectiveness of CYP2C19 genotype-guided therapy, universal clopidogrel, and universal ticagrelor in post-percutaneous coronary intervention patients in Qatar. International journal of cardiology.S0167-5273.
  24. Salem, M., Eljilany, I., El-Bardissy, A., & Elewa H. (2021). Genetic Polymorphism Effect on Warfarin–Rifampin Interaction: A Case Report and Review of Literature. Pharmacogenomics and Personalized Medicine. 14, 149-156.
  25. Mohamed MFH, Al-Shokri SD, Shunnar KM, Mohamed SF, Najim MS, Ibrahim SI, Elewa H, Abdalla LO, El-Bardissy A, Elshafei MN, Abubeker IY, Danjuma M, Dousa KM, Yassin MA (2021) Prevalence of venous thromboembolism in critically ill COVID-19 patients: systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 7 (338).
  26. Al Hamed, F. A., & Elewa, H. (2020). Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.  Clinical therapeutics. S0149-2918.
  27. El-Bardissy A, Elewa H, Khalil A, Mekkawi W, Mohammed S, Kassem M, Alma’moon MM, Abdelgelil M, Eltorki Y, Mohamed FA. (2020). Assessing Pharmacists Knowledge and Attitude Toward the Direct Oral Anticoagulants in Qatar. Clinical and Applied Thrombosis/Hemostasis. Jun 29;26:1076029620933946.
  28. Alhmoud E, Abdelsamad O, Soaly E, El Enany R, Elewa H. (2020). Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar. Journal of thrombosis and thrombolysis. 2020 Jul 3:1-4.
  29. Mohamed MF, Elewa H, Mubasher M, Danjuma M. (2020). Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients. Journal of Thrombosis and Thrombolysis. Jul 31:1-2.
  30. Elshafei MN, Mohamed MFH, El-Bardissy A, Ahmed MB, Abdallah I, Elewa H, Danjuma M. (2020) Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. Journal of thrombosis and thrombolysis. doi:10.1007/s11239-020-02179-4
  31. Al‐Sulaiti FK, Nader A, El‐Mekaty E, Elewa H, Al‐Badriyeh D, El‐Zubair A, Saad MO, Awaisu A. (2020).  Vancomycin therapeutic drug monitoring service quality indices and clinical effectiveness outcomes: A retrospective cohort and clinical audit. Journal of the American College of Clinical Pharmacy. Jun;3(4):778-85.
  32. Eljilany I, El-Bardissy A, Nemir A, Elzouki AN, El Madhoun I, Al-Badriyeh D, Elewa H. (2020). Assessment of the attitude, awareness and practice of periprocedural warfarin management among health care professional in Qatar. A cross sectional survey. Journal of Thrombosis and Thrombolysis. Apr 19:1-2.
  33. Elewa H, Qurishi I, Abouelhassan R, Abou Safrah S, Alhamoud E, Bader L (2020) Effect of SAMe-TT2R2 score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin. Journal of thrombosis and thrombolysis. doi:10.1007/s11239-020-02102-x
  34. AlMukdad S, Elewa H, Al-Badriyeh D (2020) Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics 25 (3):201-211. doi:10.1177/1074248420902298
  35.  Bader L, Mahfouz A, Kasem M, Mohammed S, Alsaadi S, Abdelsamad O, Elenani R, Soaly E, Elzouki A, Rizk N, Khalifa S, Shahin MH, Cavallari LH, Mraiche F, Elewa H (2020) The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population. The pharmacogenomics journal 20 (2):277-284. doi:10.1038/s41397-019-0116-y
  36. Elewa H, Awaisu A (2019) Pharmacogenomics In Pharmacy Practice: Current Perspectives. Integr Pharm Res Pract 8:97-104. doi:10.2147/iprp.S180154
  37. Al-Sulaiti, F.K., Nader, A.M., Saad, M.O., Shaukat, A., Parakadavathu, R., Elzubair, A., Al-Badriyeh, D.,Elewa, H and Awaisu, A., 2019. Clinical and Pharmacokinetic Outcomes of Peak–Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial. European journal of drug metabolism and pharmacokinetics, pp.1-14.
  38. Ali, Z., & Elewa, H. (2019). The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/1076029619875520
  39. Fahmi, A. M., Mohamed, A., Elewa, H., & Saad, M. O. (2019). Preemptive Dose Adjustment Effect on the Quality of Anticoagulation Management in Warfarin Patients With Drug Interactions: A Retrospective Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 25, 1076029619872554.
  40. Al Mukdad, M., Al-Badriyeh, D., & Elewa, H. (2019). Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review. Clinical and Applied Thrombosis/Hemostasis, 25, 1076029619849103.
  41. Diab MI, Nasr ZG, El-Hajj MS, Elewa H, El-Geed HA, Wilby KJ. (2019) Exploring the Influence of Language on Assessment Given a Mismatch Between Language of Instruction and Language of Practice. Simulation in Healthcare Publish Ahead of Print. doi:10.1097/sih.0000000000000358
  42. El-Bardissy, A., Elewa, H., Mohammed, S., Shible, A., Imanullah, R., & Mohammed, A. M. (2018). A Survey on the Awareness and Attitude of Physicians on Direct Oral Anticoagulants in Qatar. Clinical and Applied Thrombosis/Hemostasis, 255S-260S. https://doi.org/10.1177/1076029618807575
  43. Paravattil, B, Elewa, H. Approaches to Direct Oral Anticoagulant Selection in Practice. Journal of Cardiovascular Pharmacology and Therapeutics. 2018:1074248418793137.
  44. Al-Shaer, MH, Elewa, H, Alkabab, Y, Nazer, LH, Heysell, SK. Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar. BMC Infect Dis. 18.1 (2018): 384.
  45. Chang, C, Hoyos, M, Owusu, Y, Elewa, H. Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions. Ann Pharmacother. 52.2 (2018): 185-197.
  46. Elewa, H, El-Makaty, H, Ali, Z. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience. Journal of Cardiovascular Pharmacology and Therapeutics. 23.2 (2018): 155-161
  47. Dagenais, R, Wilby, KJ, Elewa, H, Ensom, MH. Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region. Drugs R D. 17.3 (2017): 341-361.
  48. Al-Shaer, M. H., Mansour, H., Elewa, H., Salameh, P., & Iqbal, F. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC Infectious Diseases, 17.1 (2017): 118.
  49. Elewa, H., Alhaddad, A., Al-Rawi, S., Nounou, A., Mahmoud, H., & Singh, R. Trends in oral anticoagulant use in Qatar: a 5-year experience. J Thromb Thrombolysis, 43.3 (2017): 411-416.
  50. Paravattil, B., & Elewa, H. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome. Journal of Cardiovascular Pharmacology and Therapeutics, 22.4 (2017): 347-355.
  51. Elewa, H., & Wilby, K. J. A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications. European Journal of Drug Metabolism and Pharmacokinetics, 42.5 (2017): 745-756.
  52. Bader, L. A., & Elewa, H. (2016). The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review. PLoS One, 11.12 (2016): e0168732.
  53. Elewa, H., Ahmed, D., & Barnes, G. D. (2016). Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting: Searching for the best combination. Seminars in thrombosis and hemostasis. Vol. 42. No. 06. 662-670. Thieme Medical Publishers, 2016
  54. Fahmi, A., Abdelsamad, O., & Elewa, H. (2016). Rifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report. SpringerPlus, 5(1), 8.  Retrieved from http://www.springerplus.com/content/5/1/8
  55. Elewa, H., Jalali, F., Khudair, N., Hassaballah, N., Abdelsamad, O., & Mohammed, S. Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar. J Eval Clin Pract, 22.3 (2016): 433-438.
  56. Elewa, H., AbdelSamad, O., Elmubark, A., Al‐Taweel, H., Mohamed, A., Kheir, N., Mohamed Ibrahim, M.I. and Awaisu, A. The first pharmacist‐managed anticoagulation clinic under a collaborative practice agreement in Qatar: clinical and patient‐oriented outcomes. Journal of clinical pharmacy and therapeutics. 41.4 (2016): 403-408.
  57. Elewa, H., Elrefai, R., & Barnes, G. D. Cancer-Associated Venous Thromboembolism. Current treatment options in cardiovascular medicine, 18.4 (2016): 23
  58. Elewa, H., El-Mekaty, E., El-Bardissy, A., Ensom, M. H., & Wilby, K. J. Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clinical pharmacokinetics, 54.12 (2015): 1223-1235.
  59. Elewa, H., Alkhiyami, D., Alsahan, D., & Abdel‐Aziz, A. A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. J Eval Clin Pract. 21.4 (2015): 703-709.
  60. Stoudenmire, L. G., DeRemer, C. E., & Elewa, H. Telephone versus office-based management of warfarin: impact on international normalized ratios and outcomes. International journal of hematology, 100.2 (2014): 119-124.
  61. Elewa, H. F., DeRemer, C. E., Keller, K., Gujral, J., & Joshua, T. V. Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis, 38.1 (2014): 115-120.
  62. Kimmel, S. E., French, B., Kasner, S. E., Johnson, J. A., Anderson, J. L., Gage, B. F., Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ. A pharmacogenetic versus a clinical algorithm for warfarin dosing. New England Journal of Medicine, 369.24 (2013): 2283-2293. Retrieved from https://www.nejm.org/doi/suppl/10.1056/NEJMoa1310669/suppl_file/nejmoa1310669_appendix.pdf
  63. Niu, Y., Gong, Y., Langaee, T. Y., Davis, H. M., Elewa, H., Beitelshees, A. L., Moss, J.I., Cooper-DeHoff, R.M., Pepine, C.J., Johnson, J. A. Genetic Variation in the β2 Subunit of the Voltage-Gated Calcium Channel and Pharmacogenetic Association With Adverse Cardiovascular Outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES) Clinical Perspective. Circulation: Cardiovascular Genetics, 3.6 (2010): 548.
  64. Elewa, H. F., El‐Remessy, A. B., Somanath, P. R., & Fagan, S. C. (2010). Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 30(2), 169-176.
  65. Kozak, A., Ergul, A., El-Remessy, A. B., Johnson, M. H., Machado, L. S., Elewa, H. F., Abdelsaid, M., Wiley, D.C, Fagan, S. C. (2009). Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke, 40(5), 1870-1876.
  66. Elewa, H. F., Kozak, A., El-Remessy, A. B., Frye, R. F., Johnson, M. H., Ergul, A., & Fagan, S. C. (2009). Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. Journal of Pharmacology and Experimental Therapeutics, 330(2), 532-540.
  67. Kozak, W., Kozak, A., Johnson, M. H., Elewa, H. F., & Fagan, S. C. (2008). Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. Journal of Pharmacology and Experimental Therapeutics, 326(3), 773-782.
  68. Elgebaly, M. M., Kelly, A., Harris, A. K., Elewa, H., Portik-Dobos, V., Ketsawatsomkron, P., Marrero, M., Ergul, A. (2008). Impaired insulin-mediated vasorelaxation in a nonobese model of type 2 diabetes: role of endothelin-1 This article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in Endothelin. Canadian journal of physiology and pharmacology, 86(6), 358-364.
  69. Sigurdsson, S. T., Strandgaard, S., Elewa, H. F., Kozak, A., Johnson, M. H., Ergul, A., & Fagan, S. C. Blood Pressure Lowering After Experimental Cerebral Ischemia Provides Neurovascular Protection. Commentary. Journal Of Hypertension, 25.4 (2007)
  70. Fagan, S. C., Elewa, H. F., & Rychly, D. J. (2007). Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice. Journal of Pharmacy Practice, 20(2), 117-122.
  71. Ergul, A., Elgebaly, M. M., Middlemore, M.-L., Li, W., Elewa, H., Switzer, J. A., . . . Fagan, S. C. (2007). Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC neurology, 7(1), 33.
  72. Elewa, H. F., Kozak, A., Johnson, M. H., Ergul, A., & Fagan, S. C. (2007). Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. Journal of Hypertension, 25(4), 855-859.
  73. Elewa, H. F., Hilali, H., Hess, D. C., Machado, L. S., & Fagan, S. C. (2006). Minocycline for Short‐Term Neuroprotection. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 26(4), 515-521.

Book Chapters:

  1. Omar, N. E., Afifi, H. M., Sahal, A. O., Mekkawi, R., Elewa, H.. The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. In: Raza, A. , editor. Immune Checkpoint Inhibitors – New Insights and Recent Progress [Working Title] [Internet]. London: IntechOpen; 2022 [cited 2022 Nov 26]. Available from: https://www.intechopen.com/online-first/84453 doi:10.5772/intechopen.107833
  2. Elewa H. Medical devices for pharmacy-based anticoagulant services. Medical Devices for Pharmacy Profession (2020). Taylor and Francis
  3.  Gujral J, Elewa HF, (2013). Clinical Medicine – A Practical Manual for  Emergency Medicine and Tropical Disease. In BB. Rewari (Ed), Recent advances in anticoagulation therapy (pp.150-156). New Delhi, India: Jaypee Brothers Medical publishers